Clinical Trial

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Study acronym: FLINN
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a single center, phase Ib/II study combining an anti-PD-1 antibody and an anti-CTLA-4 antibody with IL-15. It is testing the hypothesis that the addition of nogapendekin alfa inbakicept to nivolumab and ipilimumab will augment the clinical activity of those two drugs.
Protocol Amendment History 8 changes
critical Recruitment opened 2026-07-11
critical Phase changed: ['PHASE2'] -> ['PHASE1', 'PHASE2'] 2026-07-03
critical Primary endpoint(s) modified 2026-07-03
minor Trial arms changed: 1 -> 3 2026-07-03
notable Primary completion pushed: 2032-06-30 -> 2032-07-31 2026-07-03
minor Completion pushed: 2032-06-30 -> 2032-07-31 2026-07-03
notable Primary completion pushed: 2032-03-31 -> 2032-06-30 2026-05-23
minor Completion pushed: 2032-03-31 -> 2032-06-30 2026-05-23
Trial Details
NCT Number NCT07355205
Lead Sponsor Washington University School of Medicine
Collaborators: ImmunityBio, Inc., The Foundation for Barnes-Jewish Hospital
Conditions Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
Enrollment 26 participants
Start Date 2026-07-07
Primary Completion 2032-07-31 (estimated)
Study Completion 2032-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-10